je.st
news
Tag: merck
KEYTRUDA (pembrolizumab) from Merck Awarded Prix Galien USA 2015 Best Biotechnology Product Award
2015-10-28 13:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy for the treatment of advanced melanoma and metastatic non-small cell lung cancer in patients whose disease has progressed after other therapies, received the Prix Galien USA 2015 Award for Best Biotechnology Product. Language: English Contact: Media:Pamela Eisele, 267-305-3558 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Merck beats 3Q net income expectations, misses revenue forecasts
2015-10-28 05:29:52| Biotech - Topix.net
The drugmaker Merck & Co. on Tuesday said its third-quarter profit more than doubled, as heavy cost-cutting from its ongoing restructuring more than offset lower sales and the impact of unfavourable currency exchange rates.
Tags: net
income
revenue
expectations
Merck tops 3Q profit forecasts
2015-10-27 12:55:49| Biotech - Topix.net
The Kenilworth, New Jersey-based company said it had profit of 64 cents per share.
Tags: profit
tops
forecasts
merck
Swiss drug maker Novartis says Q3 net income drops following sale of shares to Merck last year
2015-10-27 12:55:47| Biotech - Topix.net
Swiss pharmaceutical giant Novartis says net income fell 42 per cent in the third quarter, largely due to the sale of its hepatitis drug unit a year earlier and provisions for legal settlements and fees. The company says the integration of businesses from a multibillion-dollar product exchange with rival GlaxoSmithKline earlier this year is on track.
Merck Announces Third-Quarter 2015 Financial Results
2015-10-27 11:45:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Increased Non-GAAP EPS by 7 Percent to $0.96; GAAP EPS of $0.64 Raised 2015 Full-Year Non-GAAP EPS Target to a Range of $3.55 $3.60 and GAAP EPS Target to a Range of $1.64 $1.74 Worldwide Sales Were $10.1 Billion, a Decrease of 5 Percent; Excluding the Impact of Foreign Exchange, Acquisitions and Divestitures, Worldwide Sales Grew 4 Percent Advanced KEYTRUDA Program FDA Approved sBLA for the Treatment of Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1 In KEYNOTE-010 Study KEYTRUDA Showed Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced NSCLC Whose Tumors Express PD-L1 Third-Quarter Sales Were Approximately $160 million KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2015. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036Steven Cragle, 908-740-1801orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1789 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
financial
announces
merck
Sites : [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] next »